Improving Quality of Life with Brachytherapy for Urological Malignancies
Clinical Oncology · 2023
DOI: 10.1016/j.clon.2023.01.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Oncology, 2023. Verfasst von D Scheltes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Radiotherapy Group, Location Arnhem, Arnhem, the Netherlands. Hauptthemen laut MEDLINE: Brachytherapy, Penile Neoplasms, Prostatic Neoplasms, Urologic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Department of Health.
Abstract (Originalsprache)
Brachytherapy for localised prostate, muscle-invasive bladder and penile cancer is well established, providing high tumour dose delivery and minimising normal tissue doses compared with external beam techniques. In prostate cancer, the main impact on quality of life relates to diminished sexual function and irritative or obstructive urinary symptoms, which are seen up to 15 years after treatment. Significant changes in bowel function are rare. Compared with radical prostatectomy or external beam radiotherapy, irritative or obstructive urinary symptoms are more prominent, whereas incontinence is less than after radical prostatectomy and bowel changes are less than after external beam radiotherapy. For muscle-invasive bladder cancer, when compared with radical cystectomy, although no difference is seen for urinary symptoms or fatigue, role and social functioning scores are higher and there is better post-treatment sexual function in both men and women. Compared with surgical treatment for penile cancer, brachytherapy results in better erectile function scores than after glansectomy and partial penectomy and high quality of life scores, with good satisfaction ratings for cosmetic appearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiotherapy Group, Location Arnhem, Arnhem, the Netherlands.
- Department of Radiation Oncology, ACTREC, Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, India.
- Rijnstate Hospital, Arnhem, the Netherlands.
- Mount Vernon Cancer Centre, Northwood, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address: peterhoskin@nhs.net.
Förderung
- Department of Health
Zitieren
APA
Scheltes, D., Mohanty, S., Smits, G., van der Steen-Banasik, E., Murthy, V., & Hoskin, P. (2023). Improving Quality of Life with Brachytherapy for Urological Malignancies. Clinical Oncology. https://doi.org/10.1016/j.clon.2023.01.017
Vancouver
Scheltes D, Mohanty S, Smits G, van der Steen-Banasik E, Murthy V, Hoskin P. Improving Quality of Life with Brachytherapy for Urological Malignancies. Clinical Oncology. 2023. doi:10.1016/j.clon.2023.01.017
BibTeX
@article{Scheltes2023,
author = {Scheltes, D and Mohanty, S and Smits, G and van der Steen-Banasik, E and Murthy, V and Hoskin, P},
title = {Improving Quality of Life with Brachytherapy for Urological Malignancies},
journal = {Clinical Oncology},
year = {2023},
doi = {10.1016/j.clon.2023.01.017}
}
EUVIMED